Abiopharma

🔍 NAFDE VIKRAM A. (Executive)

Company: WEBSTER FINANCIAL CORP (WBS)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 13,865 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 46,973.85 | transaction_form_type: 4 | Footnotes: F2
• Sold 6,426 shares of Common Stock at $79.07 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 40,547.85 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,685 shares of Common Stock at $79.07 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 37,862.85 | transaction_form_type: 4 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: H | shares_owned_after: 33,108.85 | Footnotes: F1

Footnotes:

• F1: Reflects 219.686 shares purchased through Webster Financial Corporation's Employee Stock Purchase Plan, as amended and restated effective April 1, 2019, since most recent Form 4 filed on March 13, 2026.
• F2: Represents the vesting of certain performance shares that were accelerated pursuant to the Transaction Agreement, dated as of February 3, 2026, by and among Webster Financial Corporation, Banco Santander, S.A. and Webster Virginia Corporation.
• F3: Represents the tax withholding upon the vesting of certain performance shares that were accelerated pursuant to the Transaction Agreement, dated as of February 3, 2026, by and among Webster Financial Corporation, Banco Santander, S.A. and Webster Virginia Corporation.
• F4: Represents the tax withholding upon the vesting of certain time-based restricted shares that were accelerated pursuant to the Transaction Agreement, dated as of February 3, 2026, by and among Webster Financial Corporation, Banco Santander, S.A. and Webster Virginia Corporation.